[{"id":"fb5a3d64-2b8f-44c4-84f0-e927e52ab2a1","acronym":"","url":"https://clinicaltrials.gov/study/NCT04939051","created_at":"2024-02-29T18:31:43.001Z","updated_at":"2025-02-25T13:35:51.854Z","phase":"Phase 2","brief_title":"Obeticholic Acid for Prevention in Barrett's Esophagus","source_id_and_acronym":"NCT04939051","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" FGF19 • SOX2 • CASP3 • FGF • CDX2","pipe":"","alterations":" ","tags":["FGF19 • SOX2 • CASP3 • FGF • CDX2"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 01/03/2024","start_date":" 01/03/2024","primary_txt":" Primary completion: 09/29/2025","primary_completion_date":" 09/29/2025","study_txt":" Completion: 09/29/2026","study_completion_date":" 09/29/2026","last_update_posted":"2025-02-21"},{"id":"a1596462-69b2-4cbb-bcf0-d0bed5de43d8","acronym":"","url":"https://clinicaltrials.gov/study/NCT02508467","created_at":"2021-01-18T12:06:37.223Z","updated_at":"2024-07-02T16:35:09.856Z","phase":"Phase 1","brief_title":"A Phase 1 Study of Fisogatinib (BLU-554) in Patients With Hepatocellular Carcinoma","source_id_and_acronym":"NCT02508467","lead_sponsor":"Blueprint Medicines Corporation","biomarkers":" FGF19","pipe":"","alterations":" ","tags":["FGF19"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e fisogatinib (BLU-554)"],"overall_status":"Completed","enrollment":" Enrollment 146","initiation":"Initiation: 07/31/2015","start_date":" 07/31/2015","primary_txt":" Primary completion: 06/30/2021","primary_completion_date":" 06/30/2021","study_txt":" Completion: 02/28/2024","study_completion_date":" 02/28/2024","last_update_posted":"2024-04-12"},{"id":"47f92e4c-0373-4b92-b1aa-e6cda3cd31e1","acronym":"","url":"https://clinicaltrials.gov/study/NCT04828486","created_at":"2021-04-02T11:53:33.440Z","updated_at":"2024-07-02T16:35:12.332Z","phase":"Phase 2","brief_title":"Futibatinib and Pembrolizumab for Treatment of Advanced or Metastatic FGF19 Positive BCLC Stage A, B, or C Liver Cancer","source_id_and_acronym":"NCT04828486","lead_sponsor":"Mayo Clinic","biomarkers":" FGF19","pipe":" | ","alterations":" FGF19 positive","tags":["FGF19"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FGF19 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Lytgobi (futibatinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 25","initiation":"Initiation: 05/07/2021","start_date":" 05/07/2021","primary_txt":" Primary completion: 05/06/2025","primary_completion_date":" 05/06/2025","study_txt":" Completion: 05/06/2025","study_completion_date":" 05/06/2025","last_update_posted":"2024-03-29"},{"id":"43d8bb89-a022-4c97-a5c6-8d7b86cf251f","acronym":"BB102-ST-Ⅰ-02","url":"https://clinicaltrials.gov/study/NCT06258408","created_at":"2024-02-14T16:26:56.302Z","updated_at":"2024-07-02T16:35:18.596Z","phase":"Phase 1","brief_title":"A Phase 1 Study of BB102 in Participants With Advanced Solid Tumors","source_id_and_acronym":"NCT06258408 - BB102-ST-Ⅰ-02","lead_sponsor":"BrodenBio Co., Ltd.","biomarkers":" FGF19 • FGFR4","pipe":"","alterations":" ","tags":["FGF19 • FGFR4"],"overall_status":"Recruiting","enrollment":" Enrollment 78","initiation":"Initiation: 12/29/2022","start_date":" 12/29/2022","primary_txt":" Primary completion: 01/01/2025","primary_completion_date":" 01/01/2025","study_txt":" Completion: 07/01/2025","study_completion_date":" 07/01/2025","last_update_posted":"2024-02-20"},{"id":"0e8ce658-c4b0-468e-b7e3-ed2144f926f5","acronym":"","url":"https://clinicaltrials.gov/study/NCT06068257","created_at":"2023-10-05T16:11:12.195Z","updated_at":"2024-07-02T16:35:33.711Z","phase":"","brief_title":"Tumor-Derived FGF19","source_id_and_acronym":"NCT06068257","lead_sponsor":"University of Central Florida","biomarkers":" FGF19","pipe":" | ","alterations":" FGF19 elevation","tags":["FGF19"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FGF19 elevation"],"overall_status":"Recruiting","enrollment":" Enrollment 210","initiation":"Initiation: 06/06/2023","start_date":" 06/06/2023","primary_txt":" Primary completion: 06/01/2024","primary_completion_date":" 06/01/2024","study_txt":" Completion: 06/01/2024","study_completion_date":" 06/01/2024","last_update_posted":"2023-10-12"},{"id":"7ca1a5b6-b5e3-4622-8a4f-a462e3ff4894","acronym":"","url":"https://clinicaltrials.gov/study/NCT05498519","created_at":"2022-08-13T17:57:29.618Z","updated_at":"2024-07-02T16:35:48.307Z","phase":"Phase 1","brief_title":"A First-in-Human, Phase 1 Study of SY-4798 in Patients With Advanced Solid Tumor","source_id_and_acronym":"NCT05498519","lead_sponsor":"Shouyao Holdings (Beijing) Co. LTD","biomarkers":" FGF19","pipe":"","alterations":" ","tags":["FGF19"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e SY-4798"],"overall_status":"Recruiting","enrollment":" Enrollment 80","initiation":"Initiation: 04/15/2021","start_date":" 04/15/2021","primary_txt":" Primary completion: 04/15/2024","primary_completion_date":" 04/15/2024","study_txt":" Completion: 04/15/2024","study_completion_date":" 04/15/2024","last_update_posted":"2023-05-11"},{"id":"4ed498dc-5624-45ec-92f9-0152aea8082e","acronym":"FOCUS","url":"https://clinicaltrials.gov/study/NCT05718349","created_at":"2023-02-08T17:00:18.763Z","updated_at":"2024-07-02T16:35:56.122Z","phase":"","brief_title":"FGF19 in Obstructive Cholestasis: \"Unveil the Signal\"","source_id_and_acronym":"NCT05718349 - FOCUS","lead_sponsor":"Nicole Hildebrand","biomarkers":" FGF19","pipe":"","alterations":" ","tags":["FGF19"],"overall_status":"Recruiting","enrollment":" Enrollment 81","initiation":"Initiation: 01/01/2017","start_date":" 01/01/2017","primary_txt":" Primary completion: 12/01/2024","primary_completion_date":" 12/01/2024","study_txt":" Completion: 06/01/2025","study_completion_date":" 06/01/2025","last_update_posted":"2023-02-08"},{"id":"6e723a13-4912-4048-8073-6e3f7a645994","acronym":"","url":"https://clinicaltrials.gov/study/NCT05441475","created_at":"2022-09-26T15:56:05.332Z","updated_at":"2024-07-02T16:36:03.502Z","phase":"Phase 2","brief_title":"A Phase 2, Open-Label Study of ABSK-011 Combined Atezolizumab in HCC Patients","source_id_and_acronym":"NCT05441475","lead_sponsor":"Abbisko Therapeutics Co, Ltd","biomarkers":" FGF19","pipe":" | ","alterations":" FGF19 overexpression","tags":["FGF19"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FGF19 overexpression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tecentriq (atezolizumab) • irpagratinib (ABSK011)"],"overall_status":"Recruiting","enrollment":" Enrollment 62","initiation":"Initiation: 12/30/2021","start_date":" 12/30/2021","primary_txt":" Primary completion: 07/20/2024","primary_completion_date":" 07/20/2024","study_txt":" Completion: 10/10/2024","study_completion_date":" 10/10/2024","last_update_posted":"2022-09-26"},{"id":"ed4dac9d-60e5-4898-90a7-3c9baf5c0e7b","acronym":"","url":"https://clinicaltrials.gov/study/NCT05171335","created_at":"2021-12-28T19:16:19.218Z","updated_at":"2025-02-25T13:36:01.904Z","phase":"Phase 2","brief_title":"Neoadjuvant Combination Therapy of Lenvatinib and TACE for Transplant-Eligible Large Hepatocellular Carcinoma Patients","source_id_and_acronym":"NCT05171335","lead_sponsor":"The Methodist Hospital Research Institute","biomarkers":" FGF19 • PECAM1","pipe":"","alterations":" ","tags":["FGF19 • PECAM1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lenvima (lenvatinib)"],"overall_status":"Enrolling by invitation","enrollment":" Enrollment 50","initiation":"Initiation: 06/20/2022","start_date":" 06/20/2022","primary_txt":" Primary completion: 06/30/2026","primary_completion_date":" 06/30/2026","study_txt":" Completion: 12/30/2027","study_completion_date":" 12/30/2027","last_update_posted":"2022-09-21"},{"id":"7a766258-ef73-4c74-938d-a1a53533819e","acronym":"","url":"https://clinicaltrials.gov/study/NCT04365933","created_at":"2021-01-18T21:05:55.917Z","updated_at":"2024-07-02T16:36:04.856Z","phase":"Phase 2a","brief_title":"A Study of the Oral Farnesoid X Receptor Modulator EYP001a to Assess Its Safety and Anti-viral Effect in Chronic Hepatitis B Patients in Combination With Pegylated Interferon alpha2a Alone and With Entecavir","source_id_and_acronym":"NCT04365933","lead_sponsor":"Enyo Pharma","biomarkers":" FGF19","pipe":"","alterations":" ","tags":["FGF19"],"overall_status":"Completed","enrollment":" Enrollment 20","initiation":"Initiation: 05/25/2020","start_date":" 05/25/2020","primary_txt":" Primary completion: 06/16/2021","primary_completion_date":" 06/16/2021","study_txt":" Completion: 11/29/2021","study_completion_date":" 11/29/2021","last_update_posted":"2022-08-25"},{"id":"aba6b3e5-cb1f-46a6-86b7-19b8fd3e71e7","acronym":"","url":"https://clinicaltrials.gov/study/NCT04906434","created_at":"2021-05-28T13:52:37.440Z","updated_at":"2024-07-02T16:36:08.012Z","phase":"Phase 1","brief_title":"A Study to Assess the Safety, Tolerability, and Pharmacokinetics of ABSK-011 in Patients With Advanced Solid Tumor","source_id_and_acronym":"NCT04906434","lead_sponsor":"Abbisko Therapeutics Co, Ltd","biomarkers":" FGF19","pipe":" | ","alterations":" FGF19 overexpression","tags":["FGF19"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FGF19 overexpression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e irpagratinib (ABSK011)"],"overall_status":"Recruiting","enrollment":" Enrollment 50","initiation":"Initiation: 02/26/2020","start_date":" 02/26/2020","primary_txt":" Primary completion: 12/31/2023","primary_completion_date":" 12/31/2023","study_txt":" Completion: 08/31/2025","study_completion_date":" 08/31/2025","last_update_posted":"2022-06-30"},{"id":"32f83472-1781-4c9c-b734-1dab895ebbcd","acronym":"","url":"https://clinicaltrials.gov/study/NCT04003181","created_at":"2021-01-18T19:40:26.731Z","updated_at":"2024-07-02T16:36:24.706Z","phase":"","brief_title":"The Pathogenesis of Chronic Diarrhoea After Treatment for Cancer in Cecum and the Ascending Colon","source_id_and_acronym":"NCT04003181","lead_sponsor":"University of Aarhus","biomarkers":" FGF19","pipe":"","alterations":" ","tags":["FGF19"],"overall_status":"Completed","enrollment":" Enrollment 64","initiation":"Initiation: 09/28/2017","start_date":" 09/28/2017","primary_txt":" Primary completion: 05/26/2021","primary_completion_date":" 05/26/2021","study_txt":" Completion: 05/26/2021","study_completion_date":" 05/26/2021","last_update_posted":"2021-09-08"},{"id":"cc53a890-89ed-4959-a512-acb62dcd9222","acronym":"HELP-2020","url":"https://clinicaltrials.gov/study/NCT04506398","created_at":"2021-06-24T18:52:50.426Z","updated_at":"2024-07-02T16:36:28.684Z","phase":"","brief_title":"Heterogeneity and Evolution of hepatoceLlular Carcinoma in Post-transplant HCC Recurrence","source_id_and_acronym":"NCT04506398 - HELP-2020","lead_sponsor":"RenJi Hospital","biomarkers":" TP53 • TERT • CCND1 • IL6 • FGF19 • TGFB1 • AXIN1 • RPS6KA3","pipe":" | ","alterations":" CTNNB1 mutation • TERT mutation • TERT promoter mutation","tags":["TP53 • TERT • CCND1 • IL6 • FGF19 • TGFB1 • AXIN1 • RPS6KA3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CTNNB1 mutation • TERT mutation • TERT promoter mutation"],"overall_status":"Recruiting","enrollment":" Enrollment 40","initiation":"Initiation: 09/10/2020","start_date":" 09/10/2020","primary_txt":" Primary completion: 08/01/2021","primary_completion_date":" 08/01/2021","study_txt":" Completion: 08/01/2022","study_completion_date":" 08/01/2022","last_update_posted":"2021-06-24"},{"id":"a2c2a881-d186-4a3f-be02-3a38da1848d0","acronym":"","url":"https://clinicaltrials.gov/study/NCT04699643","created_at":"2021-01-19T20:50:12.745Z","updated_at":"2024-07-02T16:36:36.469Z","phase":"Phase 1/2","brief_title":"FGFR4 Inhibitor EVER4010001 in Combination With PD-1 Inhibitor Pembrolizumab in Patients With Advanced Solid Tumors","source_id_and_acronym":"NCT04699643","lead_sponsor":"EverNov Medicines (Zhuhai Hengqin) Co., Ltd","biomarkers":" FGF19","pipe":" | ","alterations":" FGF19 positive • FGF19 expression","tags":["FGF19"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FGF19 positive • FGF19 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • roblitinib (FGF401)"],"overall_status":"Recruiting","enrollment":" Enrollment 80","initiation":"Initiation: 07/30/2020","start_date":" 07/30/2020","primary_txt":" Primary completion: 06/01/2023","primary_completion_date":" 06/01/2023","study_txt":" Completion: 06/01/2023","study_completion_date":" 06/01/2023","last_update_posted":"2021-01-07"},{"id":"bad33fae-f9c7-474e-879f-6eabe449864a","acronym":"","url":"https://clinicaltrials.gov/study/NCT02038673","created_at":"2021-01-18T09:21:26.925Z","updated_at":"2024-07-02T16:37:05.880Z","phase":"Phase 1","brief_title":"An Open-label Phase I Study of Orally Available Novel Small-molecule Fibroblast Growth Factor Receptors (FGFR) 1,2,3 and 4 Inhibitor, ASP5878 at Single and Multiple Doses in Patients With Solid Tumors","source_id_and_acronym":"NCT02038673","lead_sponsor":"Astellas Pharma Inc","biomarkers":" FGF19 • FGF23","pipe":"","alterations":" ","tags":["FGF19 • FGF23"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ASP5878"],"overall_status":"Completed","enrollment":" Enrollment 86","initiation":"Initiation: 11/05/2013","start_date":" 11/05/2013","primary_txt":" Primary completion: 07/19/2017","primary_completion_date":" 07/19/2017","study_txt":" Completion: 07/19/2017","study_completion_date":" 07/19/2017","last_update_posted":"2018-10-22"},{"id":"426b20b4-7c14-4523-9184-8d93bb5edeb2","acronym":"","url":"https://clinicaltrials.gov/study/NCT02294578","created_at":"2021-01-18T10:49:07.477Z","updated_at":"2024-07-02T16:37:11.542Z","phase":"","brief_title":"Salivary Biomarkers for Non-small Cell Lung Cancer Detection","source_id_and_acronym":"NCT02294578","lead_sponsor":"PeriRx","biomarkers":" BRAF • KEAP1 • FGF19 • FRS2 • LZTS1 • CCN1","pipe":"","alterations":" ","tags":["BRAF • KEAP1 • FGF19 • FRS2 • LZTS1 • CCN1"],"overall_status":"Unknown status","enrollment":" Enrollment 166","initiation":"Initiation: 12/01/2014","start_date":" 12/01/2014","primary_txt":" Primary completion: 12/01/2018","primary_completion_date":" 12/01/2018","study_txt":" Completion: 03/01/2019","study_completion_date":" 03/01/2019","last_update_posted":"2018-04-12"}]